(Q47920784)

English

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.

scientific article published on 24 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

phase III clinical trial

0 references

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Christiane Copie Bergman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Philippe Gaulard

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Thierry J Molina

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

T Petrella

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J Brière

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

R Delarue

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

F Jardin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

P Ruminy

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

C Thieblemont

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

D Canioni

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

P Feugier

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

B Fabiani

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M Parrens

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M André

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

G A Salles

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

H Tilly

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J P Jais

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

1 May 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1042-1049

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Identifiers

10.1093/ANNONC/MDX022

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47920784&oldid=1527277238"